Citations

Clear

3138 citation(s) found for "Smith, AM".

Efficacy of Ganciclovir in Liver and Kidney Transplant Recipients with Severe Cytomegalovirus Infection
Paya, C. V., Hermans, Paul E., Smith, Thomas F., Rakela, Jorge , Wiesner, Russell H., Krom, Ruud A. F., Sterioff, Sylvester, Wilkowske, Conrad J., Torres, Vicente E.

Mayo Clinic

Journal of Urology | June 30, 2017 | Volume: 141 | Issue: 6 | Pages: 1505-1505

10.1016/s0022-5347(17)41371-1 Get It

Laxative Abuse as a Cause for Ammonium Urate Renal Calculi
Dick, W., Lingeman, James E., Preminger, Glenn M. , Smith, Lynwood H., Wilson, David M. , Shirrell, William L.

Mayo Clinic

Journal of Urology | June 30, 2017 | Volume: 143 | Issue: 2 | Pages: 244-247

10.1016/s0022-5347(17)39923-8 | PMID 2299711 Get It

Chlamydia and Non-Specific Urethritis
Segura, Joseph W., Smith, Thomas F., Weed, Lyle A., Pettersen, George R.

Mayo Clinic

Journal of Urology | June 29, 2017 | Volume: 117 | Issue: 6 | Pages: 720-721

10.1016/s0022-5347(17)58599-7 | PMID 577509 Get It

Using claims data linked with electronic health records to monitor and improve adherence to medication
Lobo, Jennifer M. , Wilson, James R. , Shah, N. D., Smith, Steven A., Denton, Brian T.

Mayo Clinic

IISE Transactions on Healthcare Systems Engineering | June 29, 2017 | Volume: 7 | Issue: 4 | Pages: 194-214

10.1080/24725579.2017.1346728 Get It

Congenital Absence of Testis. A Report of Seven Cases of Monorchidism
Counseller, Virgil S., Nichols, Donald R., Smith, Harry L.

Mayo Clinic

Journal of Urology | June 29, 2017 | Volume: 44 | Issue: 2 | Pages: 237-241

10.1016/s0022-5347(17)71266-9 Get It

The Null Effect of Bladder Neck Size on Incontinence Outcomes after Radical Prostatectomy
Tyson, Mark D. , Ark, Jacob , Gregg, Justin R. , Johnsen, Niels V. , Kappa, Stephen F., Lee, Daniel J. , Smith, Joseph A.

Mayo Clinic

Journal of Urology | June 24, 2017 | Volume: 198 | Issue: 6 | Pages: 1404-1408

10.1016/j.juro.2017.06.084 | PMID 28655528 Get It

Healthcare Provider Education to Support Integration of Pharmacogenomics in Practice: The Emerge Network Experience
Vitek, Carolyn R. Rohrer , Abul‐Husn, Noura S. , Connolly, John J. , Hartzler, Andrea L. , Kitchner, Terrie, Peterson, Josh F. , Rasmussen, Luke V. , Smith, Maureen E. , Stallings, Sarah , Wolf, Wendy A. , Prows, Cynthia A. , Rohrer Vitek, Carolyn R, Williams, Marc S , Rasmussen, Luke V , Connolly, John J , Peterson, Josh F

Mayo Clinic

Pharmacogenomics | June 22, 2017 | Volume: 18 | Issue: 10 | Pages: 1013-1025

10.2217/pgs-2017-0038 | PMID 28639489 Get It

Characterising cis -regulatory variation in the transcriptome of histologically normal and tumour-derived pancreatic tissues
Lykke‐Andersen, Søren , Zhu, Bin , Xiao, Wenming , Hoskins, Jason W. , Zhang, Xijun , Rost, Lauren M., Collins, Irene , Bunt, Martijn van de , Jia, Jinping , Song, Lei , Jermusyk, Ashley , Chung, Charles C., Zhou, Weiyin , Matters, Gail L. , Kurtz, Robert C. , Jensen, Torben Heick , Brown, Kevin M., Ongen, Halit , Bamlet, William R. , Murray, Bradley A., McCarthy, Mark I. , Chatterjee, Nilanjan , Wolpin, Brian M. , Petersen, Gloria M. , Shi, Jianxin , Ámundadóttir, Laufey T. , Amundadottir, Laufey , Zhang, Mingfeng , Jia, Jinping, Parikh, Hemang M. , Zhang, Tongwu , Yeager, Meredith , Chanock, Stephen Jacob , Smith, Jill Palmer , Olson, Sara H. , Bamlet, William R , McCarthy, Mark I , Hoskins, Jason W

Mayo Clinic

Gut | June 20, 2017 | Volume: 67 | Issue: 3 | Pages: 521-533

10.1136/gutjnl-2016-313146 | PMID 28634199 Get It

Objective To elucidate the genetic architecture of gene expression in pancreatic tissues. Design We performed expression quantitative trait locus (eQTL) analysis in histologically normal pancreatic tissue samples (n=95) using RNA sequencing and the corresponding 1000 genomes imputed germline genotypes. Data from pancreatic tumour-derived tissue samples (n=115) from The Cancer Genome Atlas were included for comparison. Results We identified 38 615 cis -eQTLs (in 484 genes) in histologically normal tissues and 39 713 cis -eQTL (in 237 genes) in tumour-derived tissues (false discovery rate <0.1), with the strongest effects seen near transcriptional start sites. Approximately 23% and 42% of genes with significant cis -eQTLs appeared to be specific for tumour-derived and normal-derived tissues, respectively. Significant enrichment of cis -eQTL variants was noted in non-coding regulatory regions, in particular for pancreatic tissues (1.53-fold to 3.12-fold, p≤0.0001), indicating tissue-specific functional relevance. A common pancreatic cancer risk locus on 9q34.2 (rs687289) was associated with ABO expression in histologically normal (p=5.8×10 −8 ) and tumour-derived (p=8.3×10 −5 ) tissues. The high linkage disequilibrium between this variant and the O blood group generating deletion variant in ABO (exon 6) suggested that nonsense-mediated decay (NMD) of the ‘O’ mRNA might explain this finding. However, knockdown of crucial NMD regulators did not influence decay of the ABO ‘O’ mRNA, indicating that a gene regulatory element influenced by pancreatic cancer risk alleles may underlie the eQTL. Conclusions We have identified cis -eQTLs representing potential functional regulatory variants in the pancreas and generated a rich data set for further studies on gene expression and its regulation in pancreatic tissues.
Expanded phenotypes and outcomes among 256 LGI 1/ CASPR 2‐ I g G
Gadoth, Avi , Pittock, Sean J. , Dubey, Divyanshu , McKeon, Andrew , Britton, Jeff W., Schmeling, John E., Smith, Aurelia, Watson, Robert E. , Flanagan, Eoin P. , Lennon, Vanda A. , Klein, Christopher J. , Kotsenas, Amy L. , Watson, Robert E , Pittock, S J , Britton, Jeffrey W. , Lachance, Daniel Honore , Flanagan, E P , Klein, Christopher J , McKeon, Andrew , Dubey, Divyanshu

Mayo Clinic

Annals of Neurology | June 19, 2017 | Volume: 82 | Issue: 1 | Pages: 79-92

10.1002/ana.24979 | PMID 28628235 Get It

Objective To describe an expanded phenotypic spectrum and longitudinal outcome in 256 LGI1‐IgG–seropositive and/or CASPR2‐IgG–seropositive patients. Methods Patients were identified through service neural autoantibody evaluation. Ninety‐five had longitudinal follow‐up (7–456 months; median = 35). Results Among 3,910 patients tested, 196 were LGI1‐IgG positive, 51 were CASPR2‐IgG positive, and 9 were dual positive. Cerebrospinal fluid testing was less sensitive than serum testing, detecting only 24 of 38 (63%) LGI1‐IgG–positive and 5 of 6 (83%) CASPR2‐IgG–positive patients. LGI1‐IgG–positive specimens had higher voltage‐gated potassium channel–IgG immunoprecipitation values (0.33nmol/l, range = 0.02–5.14) than CASPR2‐IgG–positive specimens (0.10nmol/l, range = 0.00–0.45, p < 0.001). Of patients presenting with pain or peripheral nervous system (PNS) manifestations, 39% were LGI1‐IgG seropositive (7% had solely neuropathy or pain). Multivariate analysis identified age as the only significant predictor of central nervous system (CNS) versus PNS involvement (>50 years; odds ratio = 15, p < 0.001). Paroxysmal dizziness spells (PDS), a unique LGI1‐IgG accompaniment (14% of patients), frequently delayed the diagnosis. T2‐mesiotemporal hyperintensity was more common in LGI1‐IgG–positive (41%) than in CASPR2‐IgG–positive patients ( p = 0.033). T1‐bright basal ganglia were confined to LGI1‐IgG–positive patients with faciobrachial–dystonic seizures (9 of 39, 31%). Cancer was found in 44% of LGI1‐IgG/CASPR2‐IgG dual seropositive patients (one‐third thymoma). Response to initial immunotherapy was favorable in 97%; mean modified Rankin score was 3 (range = 1–5) at onset and 1.74 (range = 0–6) at last follow‐up, with 9% having severe refractory disability, 20% being asymptomatic, 28% receiving immunotherapy, and 58% receiving antiepileptic medication. Interpretation Older age is a strong predictor of CNS involvement in patients seropositive for CASPR2‐IgG or LGI1‐IgG. Pain, peripheral manifestations, and stereotypic paroxysmal dizziness spells are common with LGI1‐IgG. Response to initial immunotherapy is often favorable, but some patients remain severely disabled, requiring long‐term immunotherapy and/or antiepileptic medications. Ann Neurol 2017;82:79–92
Ultrasound‐guided hydrodissection decreases gliding resistance of the median nerve within the carpal tunnel
Evers, Stefanie, Thoreson, Andrew R. , Smith, Jay , Zhao, Chunfeng , Geske, Jennifer R. , Amadio, Peter C. , Geske, Jennifer

Mayo Clinic

Muscle & Nerve | June 16, 2017 | Volume: 57 | Issue: 1 | Pages: 25-32

10.1002/mus.25723 | PMID 28622409 Get It

ABSTRACTIntroduction: The aim of this study was to assess alterations in median nerve (MN) biomechanics within the carpal tunnel resulting from ultrasound‐guided hydrodissection in a cadaveric model. Methods: Twelve fresh frozen human cadaver hands were used. MN gliding resistance was measured at baseline and posthydrodissection, by pulling the nerve proximally and then returning it to the origin. Six specimens were treated with hydrodissection, and 6 were used as controls. Results: In the hydrodissection group there was a significant reduction in mean peak gliding resistance of 92.9 ± 34.8 mN between baseline and immediately posthydrodissection (21.4% ± 10.5%; P = 0.001). No significant reduction between baseline and the second cycle occurred in the control group: 9.6 ± 29.8 mN (0.4% ± 5.3%; P = 0.467). Discussion: Hydrodissection can decrease the gliding resistance of the MN within the carpal tunnel, at least in wrists unaffected by carpal tunnel syndrome. A clinical trial of hydrodissection seems justified. Muscle Nerve 57: 25–32, 2018